Literature DB >> 7002567

Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration.

G Leonetti, L Terzoli, C Bianchini, C Sala, A Zanchetti.   

Abstract

To show whether repeated administration of atenolol for several days would influence its pharmacokinetic parameters and the extent and duration of the pharmacologic responses, the plasma level of atenolol and changes in heart rate, blood pressure and plasma renin activity were measured in 12 hypertensive patients at various times of day (9 a. m., 12 noon, 3 p. m. and 7 p. m.) after oral administration of the first dose of atenolol 100 mg, again during the 7th and 14th days of continued once-daily administration of the same dose, and finally during the three days following withdrawal of the drug. The peak plasma concentration of atenolol (about 600 ng/ml) was found 3 h after administration of the first dose, and measurable amounts (50-70 ng/ml) were found after 24 h. None of the pharmacokinetic characteristics were changed by administration of a single daily dose for two weeks. After withdrawal of the drug, detectable amounts of atenolol were found in plasma for at least 48 h. The first dose of atenolol caused prompt (3 h) and prolonged (up to 24 h) lowering of supine and standing systolic and diastolic blood pressures, slowing of supine and standing heart rate, reduction of the blood pressure and heart rate responses to dynamic exercise, and a decrease in plasma renin activity. The extent and time-course of all these responses were not influenced by repeated once-daily administration of the 100 mg dose for two weeks. Most of the effects continued during the withdrawal days, the lowering of blood pressure being somewhat more prolonged than the slowing of heart rate. It is concluded that a once-daily dose of atenolol 100 mg decreases blood pressure and heart rate throughout the following 24 h, without excessive daily fluctuation in its effects, and without signs of tolerance or accumulation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002567     DOI: 10.1007/bf00636787

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Arterial hypertension. Report of a WHO expert committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1978

2.  Dose response and frequency of administration of atenolol in essential hypertension--once daily treatment with beta-blockade.

Authors:  A J Marshall; D W Barritt; J D Harry
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Relationship between blood level of atenolol and pharmacologic effect.

Authors:  A Amery; J F De Plaen; P Lijnen; J McAinsh; T Reybrouck
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Effect of once-daily atenolol on ambulatory blood pressure.

Authors:  M W Craig; D Kenny; S Mann; V Balasubramanian; E B Raftery
Journal:  Br Med J       Date:  1979-01-27

6.  Letter: Beta receptors and renin release.

Authors:  H Aberg
Journal:  N Engl J Med       Date:  1974-05-02       Impact factor: 91.245

7.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

8.  Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

Authors:  A P Douglas-Jones; J M Cruickshank
Journal:  Br Med J       Date:  1976-04-24

9.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

10.  A comparison of once and twice daily atenolol in hypertension.

Authors:  C M Castleden; J R Dathan; C F George
Journal:  Postgrad Med J       Date:  1977-11       Impact factor: 2.401

View more
  4 in total

Review 1.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

2.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Biological sample preparation by using restricted-access nanoparticles prepared from bovine serum albumin: application to liquid chromatographic determination of β-blockers.

Authors:  Mariana Azevedo Rosa; Henrique Dipe De Faria; Diailison Teixeira Carvalho; Eduardo Costa Figueiredo
Journal:  Mikrochim Acta       Date:  2019-08-27       Impact factor: 5.833

4.  Synthesis and Characterisation of a Monolithic Imprinted Column Using a Methacrylic Acid Monomer with Porogen Propanol for Atenolol Analysis.

Authors:  Aliya Nur Hasanah; Firdha Senja Maelaningsih; Fadli Apriliandi; Akhmad Sabarudin
Journal:  J Anal Methods Chem       Date:  2020-02-28       Impact factor: 2.193

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.